Clinical characteristics and correlation of prognostic markers in 92 profiled AML patients dichotomized to the 75% percentile
| Clinical parameter . | Low miR223* . | High miR223* . | P . |
|---|---|---|---|
| Cases | (n = 69) | (n = 23) | |
| Age, y | 0.28 | ||
| median | 48 | 48 | |
| range | 17-60 | 25-60 | |
| Sex | 0.55 | ||
| male, no. (%) | 38 (55) | 11 (48) | |
| female, no. (%) | 31 (45) | 12 (52) | |
| FAB-subtype | 0.73 | ||
| M0, no. (%) | 1 (2) | 0 (0) | |
| M1, no. (%) | 7 (10) | 2 (9) | |
| M2, no. (%) | 16 (23) | 4 (17) | |
| M4, no. (%) | 30 (43) | 11 (48) | |
| M5, no. (%) | 11 (16) | 3 (13) | |
| M6, no. (%) | 1 (2) | 2 (9) | |
| M7, no. (%) | 0 | 0 (0) | |
| missing data, no. (%) | 3 (4) | 1 (4) | |
| Percentage blasts in sample | 0.25 | ||
| median (%) | 80 | 75 | |
| missing data, no. (%) | 5 | 0 | |
| Type of AML | 0.85 | ||
| de novo. no. (%) | 61 (88) | 20 (870 | |
| post MDS/secondary, no. (%) | 8 (12) | 3 (13) | |
| WBC count | 0.78 | ||
| median (×109/l) | 27 | 29 | |
| range (×109/l) | 1-328 | 1-170 | |
| ECOG performance status | 0.14 | ||
| 0 or 1, no. (%) | 66 (96) | 20 (87) | |
| 2, no. (%) | 3 (4) | 3 (13) | |
| FLT3-ITD | 0.42 | ||
| mutated, no. (%) | 21 (30) | 5 (22) | |
| NPM1 | 0.33 | ||
| mutated, no. (%) | 36 (52) | 15 (65) | |
| missing, no. (%) | 5 (7) | 1 (4) | |
| NPM1 mutated/FLT3-ITD negative | 0.25 | ||
| low risk, no. (%) | 23 (33) | 11 (48) | |
| missing, no. (%) | 5 (7) | 1 (4) | |
| CEBPA | 0.51 | ||
| mutated, no. (%) | 10 (14) | 5 (22) | |
| missing, no. (%) | 5 (7) | 0 (0) |
| Clinical parameter . | Low miR223* . | High miR223* . | P . |
|---|---|---|---|
| Cases | (n = 69) | (n = 23) | |
| Age, y | 0.28 | ||
| median | 48 | 48 | |
| range | 17-60 | 25-60 | |
| Sex | 0.55 | ||
| male, no. (%) | 38 (55) | 11 (48) | |
| female, no. (%) | 31 (45) | 12 (52) | |
| FAB-subtype | 0.73 | ||
| M0, no. (%) | 1 (2) | 0 (0) | |
| M1, no. (%) | 7 (10) | 2 (9) | |
| M2, no. (%) | 16 (23) | 4 (17) | |
| M4, no. (%) | 30 (43) | 11 (48) | |
| M5, no. (%) | 11 (16) | 3 (13) | |
| M6, no. (%) | 1 (2) | 2 (9) | |
| M7, no. (%) | 0 | 0 (0) | |
| missing data, no. (%) | 3 (4) | 1 (4) | |
| Percentage blasts in sample | 0.25 | ||
| median (%) | 80 | 75 | |
| missing data, no. (%) | 5 | 0 | |
| Type of AML | 0.85 | ||
| de novo. no. (%) | 61 (88) | 20 (870 | |
| post MDS/secondary, no. (%) | 8 (12) | 3 (13) | |
| WBC count | 0.78 | ||
| median (×109/l) | 27 | 29 | |
| range (×109/l) | 1-328 | 1-170 | |
| ECOG performance status | 0.14 | ||
| 0 or 1, no. (%) | 66 (96) | 20 (87) | |
| 2, no. (%) | 3 (4) | 3 (13) | |
| FLT3-ITD | 0.42 | ||
| mutated, no. (%) | 21 (30) | 5 (22) | |
| NPM1 | 0.33 | ||
| mutated, no. (%) | 36 (52) | 15 (65) | |
| missing, no. (%) | 5 (7) | 1 (4) | |
| NPM1 mutated/FLT3-ITD negative | 0.25 | ||
| low risk, no. (%) | 23 (33) | 11 (48) | |
| missing, no. (%) | 5 (7) | 1 (4) | |
| CEBPA | 0.51 | ||
| mutated, no. (%) | 10 (14) | 5 (22) | |
| missing, no. (%) | 5 (7) | 0 (0) |